Literature DB >> 31310032

Comparing point shear wave elastography (ElastPQ) and transient elastography for diagnosis of fibrosis stage in non-alcoholic fatty liver disease.

Wai Ling Leong1, Lee Lee Lai2, Nik Raihan Nik Mustapha3, Anushya Vijayananthan1, Kartini Rahmat1, Sanjiv Mahadeva2, Wah Kheong Chan2.   

Abstract

BACKGROUND AND AIM: Transient elastography (TE) and point shear wave elastography (pSWE) are noninvasive methods to diagnose fibrosis stage in patients with chronic liver disease. The aim of this study is to compare the accuracy of the two methods to diagnose fibrosis stage in non-alcoholic fatty liver disease (NAFLD) and to study the intra-observer and inter-observer variability when the examinations were performed by healthcare personnel of different backgrounds.
METHODS: Consecutive NAFLD patients who underwent liver biopsy were enrolled in this study and had two sets each of pSWE and TE examinations by a nurse and a doctor on the same day of liver biopsy procedure. The medians of the four sets of pSWE and TE were used for evaluation of diagnostic accuracy using area under receiver operating characteristic curve (AUROC). Intra-observer and inter-observer variability was analyzed using intraclass correlation coefficients.
RESULTS: Data for 100 NAFLD patients (mean age 57.1 ± 10.2 years; male 46.0%) were analyzed. The AUROC of TE for diagnosis of fibrosis stage ≥ F1, ≥ F2, ≥ F3, and F4 was 0.89, 0.83, 0.83, and 0.89, respectively. The corresponding AUROC of pSWE was 0.80, 0.72, 0.69, and 0.79, respectively. TE was significantly better than pSWE for the diagnosis of fibrosis stages ≥ F2 and ≥ F3. The intra-observer and inter-observer variability of TE and pSWE measurements by the nurse and doctor was excellent with intraclass correlation coefficient > 0.96.
CONCLUSION: Transient elastography was significantly better than pSWE for the diagnosis of fibrosis stage ≥ F2 and ≥ F3. Both TE and pSWE had excellent intra-observer and inter-observer variability when performed by healthcare personnel of different backgrounds.
© 2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Fibroscan; Liver stiffness measurement; NAFLD; SWE; TE; pSWE

Year:  2019        PMID: 31310032     DOI: 10.1111/jgh.14782

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  8 in total

1.  Usefulness of Noncontrast MRI-Based Radiomics Combined Clinic Biomarkers in Stratification of Liver Fibrosis.

Authors:  Ru Zhao; Hong Zhao; Ya-Qiong Ge; Fang-Fang Zhou; Long-Sheng Wang; Hong-Zhen Yu; Xi-Jun Gong
Journal:  Can J Gastroenterol Hepatol       Date:  2022-06-21

2.  Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.

Authors:  Yu-Tian Cao; Liu-Lan Xiang; Fang Qi; Yu-Juan Zhang; Yi Chen; Xi-Qiao Zhou
Journal:  EClinicalMedicine       Date:  2022-07-10

3.  Comparison of point shear wave elastography and transient elastography in the evaluation of patients with NAFLD.

Authors:  Giulio Argalia; Claudio Ventura; Niccolò Tosi; Daniele Campioni; Corrado Tagliati; Marianna Tufillaro; Monica Cucco; Gianluca Svegliati Baroni; Andrea Giovagnoni
Journal:  Radiol Med       Date:  2022-03-15       Impact factor: 6.313

4.  Metabolic Syndrome Is Associated With Advanced Liver Fibrosis Among Pediatric Patients With Non-alcoholic Fatty Liver Disease.

Authors:  Yi-Wen Ting; Sui-Weng Wong; Azriyanti Anuar Zaini; Rosmawati Mohamed; Muhammad Yazid Jalaludin
Journal:  Front Pediatr       Date:  2019-11-26       Impact factor: 3.418

5.  Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data.

Authors:  Taeang Arai; Masanori Atsukawa; Akihito Tsubota; Shigeru Mikami; Hiroki Ono; Tadamichi Kawano; Yuji Yoshida; Tomohide Tanabe; Tomomi Okubo; Korenobu Hayama; Ai Nakagawa-Iwashita; Norio Itokawa; Chisa Kondo; Keiko Kaneko; Naoya Emoto; Mototsugu Nagao; Kyoko Inagaki; Izumi Fukuda; Hitoshi Sugihara; Katsuhiko Iwakiri
Journal:  Ther Adv Endocrinol Metab       Date:  2021-03-21       Impact factor: 3.565

Review 6.  Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment.

Authors:  Leen J M Heyens; Dana Busschots; Ger H Koek; Geert Robaeys; Sven Francque
Journal:  Front Med (Lausanne)       Date:  2021-04-14

7.  Novel High-Quality Sonographic Methods to Diagnose Muscle Wasting in Long-Stay Critically Ill Patients: Shear Wave Elastography, Superb Microvascular Imaging and Contrast-Enhanced Ultrasound.

Authors:  Carmen Rosa Hernández-Socorro; Pedro Saavedra; Juan Carlos López-Fernández; Federico Lübbe-Vazquez; Sergio Ruiz-Santana
Journal:  Nutrients       Date:  2021-06-29       Impact factor: 5.717

8.  Noninvasive Assessment of Liver Fibrosis with ElastPQ in Patients with Chronic Viral Hepatitis: Comparison Using Histopathological Findings.

Authors:  Dongmin Choo; Kyung Sook Shin; Ji Hye Min; Sun-Kyoung You; Kyung-Hee Kim; Jeong Eun Lee
Journal:  Diagnostics (Basel)       Date:  2022-03-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.